A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab M
Research payments
$1,807,011
Through program year 2025, $1,807,011 in research payments was reported against A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab M, across 728 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,035,120 | 505 |
| 2024 | Research | $771,891 | 223 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Gary Buchschacher Los Angeles, CA Named on 60 payments
- Carolina Bernabe Ramirez Bronx, NY Named on 42 payments
- John Strickler Durham, NC Named on 41 payments
- Jeremy Kortmansky Woodbridge, CT Named on 40 payments
- Nilesh Verma Dallas, TX Named on 33 payments
- Manuel Modiano-Revah Tucson, AZ Named on 23 payments
- Ajay Prakash Minneapolis, MN Named on 23 payments
- Purvi Shah Richmond, VA Named on 23 payments
- Victor Lin Baton Rouge, LA Named on 22 payments
- Richard Zuniga Babylon, NY Named on 22 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.